• Mashup Score: 0
    News Details - 7 month(s) ago

    To see all the news please click on the button

    Tweet Tweets with this article
    • Unstoppable #GLP1RA semaglutide ‼️ #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis. More protection for our patients. https://t.co/qGtV75oaxZ https://t.co/d6mFOIwnwf